$285.30
+1.80
(+0.63%)
As of Oct 7, 2026, 2:48 PM EDT
Price history
Today's analyst average
Analyst average over timeIndividual analyst targets
Analyst history starts Jul 20, 2026, the first target we tracked for VEEV.
Veeva Systems (VEEV) is trading up at $285.30 (+0.63%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
Analyst price targets on VEEV
Current price targets from 5 firms average $277, median $300, ranging from $225 to $320 — the average is 3% below the current $285. Each is tracked to its date and scored the same way a member's call is.
- Piper Sandler $282 → $320 by Aug 2027 Aug 27, 2026 via Investing.com · Piper Sandler's track record
- Stifel $282 → $300 by Aug 2027 Aug 27, 2026 via Investing.com · Stifel's track record
- Needham $282 → $310 by Aug 2027 Aug 27, 2026 via Investing.com · Needham's track record
- Stifel $238 → $275 by Aug 2027 Aug 17, 2026 via Investing.com · Stifel's track record
- Guggenheim $185 → $232 by Jul 2027 Jul 22, 2026 via Investing.com · Guggenheim's track record
- Oppenheimer $197 → $225 by Jul 2027 Jul 20, 2026 via Investing.com · Oppenheimer's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Veeva Systems revenue & net income history (FY2017–FY2026)
RevenueNet income
| FY2017Jan 2017 | FY2018Jan 2018 | FY2019Jan 2019 | FY2020Jan 2020 | FY2021Jan 2021 | FY2022Jan 2022 | FY2023Jan 2023 | FY2024Jan 2024 | FY2025Jan 2025 | FY2026Jan 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $550.5M | $690.6M | $862.2M | $1.10B | $1.47B | $1.85B | $2.16B | $2.36B | $2.75B | $3.20B |
| Growth (year over year) | +34.5% | +25.4% | +24.9% | +28.1% | +32.7% | +26.3% | +16.4% | +9.7% | +16.2% | +16.3% |
| Gross profit | $376.9M | $479.1M | $616.9M | $800.7M | $1.06B | $1.35B | $1.55B | $1.69B | $2.05B | $2.41B |
| Gross margin | 68.5% | 69.4% | 71.6% | 72.5% | 72.1% | 72.8% | 71.7% | 71.3% | 74.5% | 75.5% |
| Operating income | $120.7M | $157.9M | $222.9M | $286.2M | $377.8M | $505.5M | $459.1M | $429.3M | $691.4M | $916.4M |
| Operating margin | 21.9% | 22.9% | 25.8% | 25.9% | 25.8% | 27.3% | 21.3% | 18.2% | 25.2% | 28.7% |
| Net income | $77.6M | $151.2M | $229.8M | $301.1M | $380.0M | $427.4M | $487.7M | $525.7M | $714.1M | $908.9M |
| Net margin | 14.1% | 21.9% | 26.7% | 27.3% | 25.9% | 23.1% | 22.6% | 22.2% | 26.0% | 28.4% |
| EPS (diluted) | $0.53 | $0.98 | $1.47 | $1.90 | $2.36 | $2.63 | $3.00 | $3.22 | $4.32 | $5.44 |
| Balance sheet | ||||||||||
| Cash and equivalents | $217.6M | $320.2M | $551.0M | $476.7M | $730.5M | $1.14B | $886.5M | $703.5M | $1.12B | $1.42B |
| Total assets | $917.4M | $1.23B | $1.65B | $2.27B | $3.05B | $3.82B | $4.80B | $5.91B | $7.34B | $8.98B |
| Total liabilities | $264.7M | $324.1M | $416.0M | $606.2M | $779.7M | $904.8M | $1.09B | $1.27B | $1.51B | $1.76B |
| Shareholders' equity | $678.2M | $906.2M | $1.24B | $1.67B | $2.27B | $2.91B | $3.72B | $4.64B | $5.83B | $7.21B |
| Cash flow | ||||||||||
| Operating cash flow | $144.0M | $233.4M | $310.8M | $437.4M | $551.2M | $764.5M | $780.5M | $911.3M | $1.09B | $1.42B |
| Capital expenditure | $6.92M | $9.63M | $8.44M | $3.11M | — | — | — | — | — | — |
| Free cash flow | $137.1M | $223.8M | $302.4M | $434.3M | — | — | — | — | — | — |
| Share buybacks | — | — | — | — | — | — | — | $0 | $0 | $169.9M |
RevenueNet income
| Q3 FY25Oct 2024 | Q4 FY25†Jan 2025 | Q1 FY26Apr 2025 | Q2 FY26Jul 2025 | Q3 FY26Oct 2025 | Q4 FY26†Jan 2026 | Q1 FY27Apr 2026 | Q2 FY27Jul 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $699.2M | $720.9M | $759.0M | $789.1M | $811.2M | $836.0M | $882.9M | $928.0M |
| Growth (year over year) | +13.4% | +14.3% | +16.7% | +16.7% | +16.0% | +16.0% | +16.3% | +17.6% |
| Gross profit | $524.8M | $539.9M | $585.2M | $593.8M | $611.8M | $622.5M | $662.0M | $696.0M |
| Gross margin | 75.1% | 74.9% | 77.1% | 75.3% | 75.4% | 74.5% | 75.0% | 75.0% |
| Operating income | $181.4M | $188.4M | $233.7M | $195.9M | $240.9M | $245.9M | $273.1M | $275.0M |
| Operating margin | 25.9% | 26.1% | 30.8% | 24.8% | 29.7% | 29.4% | 30.9% | 29.6% |
| Net income | $185.8M | $195.6M | $228.2M | $200.3M | $236.2M | $244.2M | $260.9M | $273.4M |
| Net margin | 26.6% | 27.1% | 30.1% | 25.4% | 29.1% | 29.2% | 29.6% | 29.5% |
| EPS (diluted) | $1.13 | $1.17 | $1.37 | $1.19 | $1.40 | $1.48 | $1.57 | $1.66 |
| Balance sheet | ||||||||
| Cash and equivalents | $1.04B | $1.12B | $1.96B | $1.93B | $1.66B | $1.42B | $1.90B | $1.81B |
| Total assets | $6.45B | $7.34B | $7.77B | $8.00B | $8.10B | $8.98B | $9.13B | $9.06B |
| Total liabilities | $951.5M | $1.51B | $1.55B | $1.36B | $1.06B | $1.76B | $1.83B | $1.63B |
| Shareholders' equity | $5.50B | $5.83B | $6.21B | $6.64B | $7.04B | $7.21B | $7.30B | $7.43B |
| Cash flow | ||||||||
| Operating cash flow | $164.1M | $69.5M | $877.2M | $238.4M | $192.8M | $106.8M | $1.13B | $238.7M |
| Share buybacks | — | — | $0 | $0 | — | — | $226.9M | $245.7M |
From Veeva Systems's 10-K and 10-Q filings with the SEC; its fiscal year ends in January. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Veeva Systems
Veeva Systems Inc., headquartered in Pleasanton, California, provides cloud computing software, data, and consulting services for the life sciences industry. Its products are used to track all aspects of drug development and pharmaceutical manufacturing.
Source: Wikipedia — Veeva Systems
- Headquarters
- Pleasanton, California From SEC filings, Oct 2026
Recent News (20)
-
Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development More than 175 biotechs use pre-configured applications to streamline operations PLEASANTON, Calif., Oct. 7, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that more than 175 emerging …
-
Emerging Biotechs Standardize on Veeva Basics to Accelerate Drug Development More than 175 biotechs use pre-configured applications to streamline operations PLEASANTON, Calif., Oct. 7, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that more than 175 emerging …
-
SwishX Appoints Melonie Warfel as Chief Commercial Officer to Accelerate AI-Powered Content Creation for Life Sciences Former Adobe and Veeva executive joins as SwishX scales its AI-powered content platform across the life sciences industry WILMINGTON, Del., Oct. 6, 2026 /PRNewswire/ -- SwishX, an AI-powered content t…
-
-
-
Servier Adopts Veeva OpenData Globally to Scale AI Establishing an AI-ready data foundation in more than 80 countries BARCELONA, Spain, Sept. 30, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Servier is standardizing customer re…
-
-
-
-
VEEV Stock Climbs As AI Vault CRM Momentum Fuels Target Hikes VEEV Stock Climbs As AI Vault CRM Momentum Fuels Target Hikes StocksToTrade
-
Vault CRM Extends Market Leadershipas Another Top 20 Biopharma Chooses Veeva With 190 live customers and 14 top 20 biopharma commitments, Vault CRM is the fastest path to AI PLEASANTON, Calif., Sept. 23, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced a new top…
-
-
-
Veeva Expands Amgen Partnership With Global Vault CRM Rollout Plan Veeva Expands Amgen Partnership With Global Vault CRM Rollout Plan TradingView
-
-
-
-
-
-
Wells Fargo raises Veeva Systems stock price target on AI monetization potential
Wells Fargo raises Veeva Systems stock price target on AI monetization potential
More Health Care stocks
- TECH Bio-Techne
- TMO Thermo Fisher Scientific
- UHS Universal Health Services
- UNH UnitedHealth Group
- VRTX Vertex Pharmaceuticals
- VTRS Viatris
- WAT Waters Corporation
- WST West Pharmaceutical Services